U.S. Biotech Executives Sell Millions in Shares Amid Stock Surge

Enliven Therapeutics, Inc. (ELVN)’s Chief Scientific Officer Joseph P. Rishikatos and Chief Operating Officer Anish Patel sold portions of their common stock on January 8–9 under pre-arranged Section 10b5-1 trading plans. Rishikatos disposed of approximately $3.25 million (about KRW 4.7 billion) through a trust in his name, while Patel sold roughly $1.35 million (around KRW 2 billion) via a family trust. Both executives still retain substantial indirect holdings in the company.

The stock has recently surged to a 52-week high of $25.64, and its relative strength rating has climbed to 85, according to investment publications. On January 7, the company also reinforced its governance in preparation for late-stage clinical development and commercialization by adding biotech industry veteran Scott Garland to its board of directors.

Enliven Therapeutics is a clinical-stage biotech based in Boulder, Colorado, focused on developing small-molecule targeted therapies for hematologic and solid tumors. Its lead candidates, ELVN-001 and ELVN-002, are slated to enter Phase 3 trials in 2026, with additional clinical data expected in 2025. Supported by multimillion-dollar financings and existing cash reserves, the company has secured funding for its mid- to long-term R&D and operational needs.